Quarterly Report II 23/24

September 2023 – February 2024, Diamyd Medical AB (publ), Fiscal year 2023/2024Comments by CEO Ulf Hannelius Dear Shareholders, The recent granting of Fast Track designation by the U.S. FDA for our flagship product Diamyd[®] is a milestone that both accelerates the path to bringing our innovative treatment to patients with Type 1 Diabetes and validates the urgent need for our therapy. This status enhances our ability to work closely with the FDA to expedite the review process, bringing us closer to making a tangible impact on the lives of those diagnosed with Type 1 Diabetes. In